RxSight posts Q2 2026 prelim revenue of $32–34M
RxSight, Inc. announced preliminary second quarter 2026 results and updated its 2026 outlook following a strategic collaboration with Alcon.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Filing Summary
RxSight, Inc. announced preliminary second quarter 2026 results and updated its 2026 outlook following a strategic collaboration with Alcon. Q2 2026 total revenue is expected at $32 to $34 million, including $5 to $7 million from the Alcon collaboration. Product sales were about $27 million, driven by 24,917 Light Adjustable Lens units and 11 Light Delivery Devices, plus one rental placement. The company reported $209 million in cash, cash equivalents and short-term investments as of June 30, 2026. For full-year 2026, total revenue is guided to $140 to $160 million, with sales of $110 to $120 million, below prior sales guidance, and collaboration revenue of $30 to $40 million. RxSight now expects gross margin of 73% to 75%, above previous guidance, and operating expenses near the high end of $150 to $160 million, as it accelerates commercial and R&D investments.
Positive
- Higher 2026 gross margin outlook: Management raised expected 2026 gross margin to 73%–75%, above previous guidance of 70%–72%, indicating improved profitability expectations even as the company invests for growth.
- New collaboration revenue stream: 2026 guidance includes $30–$40 million of revenue from the Alcon strategic collaboration, supplementing RxSight’s core implant and device sales with partnership-driven income.
- Strong liquidity position: Cash, cash equivalents and short-term investments of approximately $209 million as of June 30, 2026 support continued commercial expansion and product development plans.
Negative
- Lowered 2026 sales guidance: Full-year 2026 sales are now projected at $110–$120 million, below previous guidance of $120–$135 million, reflecting Q2 commercial headwinds and more cautious expectations for core product demand.
- Operating expenses at high end of range: 2026 operating expense is expected at the high end of $150–$160 million, maintaining a sizable cost base as the company accelerates investments in its sales force and pipeline.
Insights
Guidance shifts toward higher margins but softer 2026 sales.
RxSight expects Q2 2026 revenue of $32–$34M, including $5–$7M from its Alcon collaboration, with core product sales of about $27M. Cash of $209M as of June 30, 2026 provides a solid funding base for ongoing growth investments.
For 2026, management guides total revenue to $140–$160M, combining $110–$120M of sales with $30–$40M of collaboration revenue. Sales guidance is below the prior $120–$135M range, reflecting Q2 commercial headwinds and more cautious expectations for the year.
At the same time, expected gross margin improves to 73%–75% from prior 70%–72%, while operating expenses are projected near the high end of $150–$160M as the company accelerates its LAL sales force and next-generation lens pipeline. Subsequent filings may provide finalized Q2 results and more detail on collaboration-related milestones.
8-K Event Classification
Key Figures
Key Terms
preliminary financial results financial
strategic collaboration financial
gross margin financial
operating expense financial
forward-looking statements regulatory
milestone payments and royalties financial
Earnings Snapshot
For 2026, RxSight projects total revenue of $140–$160 million, sales of $110–$120 million versus prior $120–$135 million, collaboration revenue of $30–$40 million, gross margin of 73%–75%, and operating expenses at the high end of $150–$160 million.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What preliminary Q2 2026 revenue did RxSight (RXST) report?
How much Q2 2026 revenue comes from RxSight’s Alcon collaboration?
What are RxSight’s 2026 full-year revenue and sales guidance ranges?
How did RxSight change its 2026 gross margin outlook?
What operating expenses does RxSight forecast for 2026?
What is RxSight’s cash position as of June 30, 2026?
How many Light Adjustable Lens units did RxSight sell in Q2 2026?
AI-generated analysis. How Rhea-AI works. Not financial advice.
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): |
(Exact name of Registrant as Specified in Its Charter)
(State or Other Jurisdiction |
(Commission File Number) |
(IRS Employer |
||
|
|
|
|
|
|
||||
|
||||
(Address of Principal Executive Offices) |
|
(Zip Code) |
||
Registrant’s Telephone Number, Including Area Code: |
|
(Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
Securities registered pursuant to Section 12(b) of the Act:
|
|
Trading |
|
|
|
|
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).
Emerging growth company
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 2.02 Results of Operations and Financial Condition.
On July 6, 2026, RxSight, Inc. (the “Company”) issued a press release announcing certain preliminary unaudited second quarter financial and operational results. A copy of the press release is furnished herewith as Exhibit 99.1.
In accordance with General Instruction B.2 of Form 8-K, the information furnished in this Current Report on Form 8-K under Item 2.02 and the exhibit attached hereto shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or incorporated by reference in any filing under the Securities Act of 1933, as amended, or in any filing under the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.
Item 9.01 Financial Statements and Exhibits.
Exhibit number |
|
Description |
99.1 |
|
Press Release dated July 6, 2026. |
104 |
|
Cover Page Interactive Data File (embedded within the inline XBRL document). |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
|
|
RxSight, Inc. |
|
|
|
|
Date: |
July 6, 2026 |
By: |
/s/ Mark Wilterding |
|
|
|
Name: Mark Wilterding |
Exhibit 99.1
RXSIGHT, INC. ANNOUNCES PRELIMINARY SECOND QUARTER FINANCIAL RESULTS AND PRODUCT PIPELINE UPDATES FOLLOWING STRATEGIC COLLABORATION AGREEMENT
Aliso Viejo, Calif. – July 6, 2026 – RxSight, Inc. (NASDAQ: RXST) today announced select preliminary financial results for the second quarter of 2026 and updates to its standalone product pipeline, following the announcement of the company’s strategic collaboration with Alcon to develop and commercialize light-adjustable Presbyopia-Correcting Intraocular Lenses.
Preliminary Second Quarter 2026 Results
Pipeline Highlights
“While we faced meaningful commercial headwinds in Q2, including from more widespread competitive trialing, the unique ability of RxSight’s Light Adjustable Technology to customize visual outcomes continued to deliver significant clinical benefits to thousands of patients around the world,” said Dr. Ron Kurtz, Chief Executive Officer and President of RxSight. “To position the company for deeper penetration of current, next-generation, and collaboration products, we are accelerating investments in our LAL sales force and commercial capabilities, while maintaining a disciplined approach to overall spending. By leveraging our differentiated technology, large customer base, strong balance sheet and exciting pipeline, we believe RxSight is well positioned to drive both high-margin implant sales and future royalty income, thereby empowering doctors to deliver the industry’s premier outcomes for even more of their patients.”
Updated Product Pipeline
RxSight is developing the first and only suite of adjustable IOLs built on its next-generation Light Adjustable Lens technology platform with improved workflow and enhanced performance. Highlights include:
Updated 2026 Guidance
The foregoing financial and operational results are preliminary estimates. RxSight is in the process of finalizing its financial statements for the second quarter of 2026, and its actual results remain subject to completion of those financial statements and their review by its independent registered public accounting firm. These preliminary estimates are based on information available to management as of the date of this press release and certain related assumptions, which could prove incorrect. RxSight’s actual, reported results of operations could differ based on completion of our quarter end closing procedures, final adjustments and developments that may arise prior to completion of its quarterly financial statements, and adjustments arising from the review by its independent registered public accounting firm. You should carefully review RxSight’s unaudited, consolidated financial statements for the second quarter of 2026 when they become available.
Conference Calls
On Tuesday, July 7, 2026, at 8:00 a.m. Eastern Time, the company will host a conference call to discuss select preliminary financial results for the second quarter of 2026, the company’s strategic collaboration and related product pipeline updates. To participate in the conference call, please dial (800) 715-9871 or (646) 307-1963 and enter the conference code: 5921122.
Separately, the company plans to report financial results for the second quarter of 2026 after the market close on Wednesday, August 5, 2026. Management will discuss more comprehensive second quarter results and provide additional updates during a conference call shortly following the announcement.
Both conference calls will also be broadcast live in listen-only mode via a link on the company’s investor relations website at https://investors.rxsight.com/. An archived recording of the calls will be available through the same link shortly after their completion.
About RxSight, Inc.
RxSight, Inc. is an ophthalmic medical device company dedicated to providing high-quality customized vision to patients following cataract surgery. The RxSight Light Adjustable Lens system, comprised of the RxSight Light Adjustable Lens (LAL/LAL+, collectively the “LAL”), RxSight Light Delivery Device (LDD) and accessories, is the first and only commercially available intraocular lens (IOL) technology that can be adjusted after surgery, enabling doctors to customize and deliver high-quality vision to patients after cataract surgery. Additional information about RxSight can be found at www.rxsight.com.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act and Section 21E of the Exchange Act. All statements in this press release that are not purely historical are forward-looking statements, including, without limitation, statements regarding our preliminary second quarter 2026 financial and operating results and the anticipated timing of announcing unaudited second quarter 2026 financial results; our projected revenue, gross margin and operating expense in 2026; our product development pipeline and anticipated timelines; potential payments that we may receive in connection with the collaboration agreement with Alcon, a description of which (including material terms and conditions) may be found in the Current Report on Form 8-K filed on or about the date hereof with the SEC, including potential milestone payments and royalties; our strategic plan; our belief that RxSight is well positioned to drive both high-margin implant sales and future royalty income, thereby empowering doctors to deliver the industry’s premier outcomes for even more of their patients; and LDD and LAL sales growth trends, including commercial headwinds.
Such statements relate to future events or our future financial performance and involve known and unknown risks, uncertainties and other factors that may cause our or our industry's actual results, levels of activity, performance or achievements to be materially different from any future results, levels of activity, performance or achievements expressed, implied or inferred by these forward-looking statements, including those relating to the strategic collaboration with Alcon (uncertainty as to whether the anticipated benefits and opportunities of the proposed collaboration may be realized or make take longer to realize or may cost more than expected; risks of unexpected hurdles, costs or delays; challenges in technology transfer and manufacturing; challenges inherent in new product candidate development, including obtaining regulatory approvals; challenges associated with collaborating with third parties, including intellectual property, operational, financial and other risks; uncertainty of commercial success for new products; the ability of RxSight and Alcon to successfully execute their respective strategic plans and those risks described in the company’s prior press releases and the company’s filings with the Securities and Exchange Commission (SEC), including in Part II, Item 1A (Risk Factors) of the company’s Quarterly Report on Form 10-Q for the period ended March 31, 2026, filed with the SEC on May 6, 2026, and any subsequent filings with the SEC. In some cases, you can identify forward-looking statements by terminology such as “may,” “will,” “should,” “could,” “would,” “expects,” “plans,” “intends,” “anticipates,” “believes,” “estimates,” “predicts,” “projects,” “potential,” or “continue” or the negative of such terms and other same terminology. These statements are only predictions based on our current expectations and projections about future events. You should not place undue reliance on these statements. Actual events or results may differ materially. In evaluating these statements, you should specifically consider various factors. These and other factors may cause our actual results to differ materially from any forward-looking statement. RxSight undertakes no obligation to update any of the forward-looking statements after the date of this press release to conform those statements to reflect the occurrence of unanticipated events, except as required by applicable law.
Investor Relations Contact:
Oliver Moravcevic
VP, Investor Relations
omoravcevic@rxsight.com